These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age. Hoegl L; Korting HC; Klebe G Pharmazie; 1999 May; 54(5):319-29. PubMed ID: 10368824 [TBL] [Abstract][Full Text] [Related]
26. Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin. Fujimoto Z; Fujii Y; Kaneko S; Kobayashi H; Mizuno H J Mol Biol; 2004 Aug; 341(5):1227-35. PubMed ID: 15321718 [TBL] [Abstract][Full Text] [Related]
27. IBC's 2nd International Conference on Protease Inhibitors: Novel Therapeutic Applications and Development, Washington DC, USA, 24-26 February 1997. Van Noorden JF Acta Histochem; 1997 Aug; 99(3):249-55. PubMed ID: 9381908 [No Abstract] [Full Text] [Related]
28. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase. Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292 [TBL] [Abstract][Full Text] [Related]
29. Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease. Naka H; Teruya K; Bang JK; Aimoto S; Tatsumi T; Konno H; Nosaka K; Akaji K Bioorg Med Chem Lett; 2006 Jul; 16(14):3761-4. PubMed ID: 16682197 [TBL] [Abstract][Full Text] [Related]
30. An artificial aspartic proteinase system. Jiang L; Liu Z; Liang Z; Gao Y Bioorg Med Chem; 2005 Jun; 13(11):3673-80. PubMed ID: 15862996 [TBL] [Abstract][Full Text] [Related]
31. Substrate specificity and molecular modelling of aspartic proteinases (cyprosins) from flowers of Cynara cardunculus subsp. flavescens cv. cardoon. Cordeiro M; Lowther T; Dunn BM; Guruprasad K; Blundell T; Pais MS; Brodelius PE Adv Exp Med Biol; 1998; 436():473-9. PubMed ID: 9561255 [No Abstract] [Full Text] [Related]
32. Proteinase inhibitors - IBC's Third International Conference. New approaches, new discoveries, new targets. Durrance A IDrugs; 2004 Feb; 7(2):140-2. PubMed ID: 15057658 [No Abstract] [Full Text] [Related]
34. Monoclonal antibodies as molecular probes to study structural heterogeneity between human and animal renins and other aspartyl proteinases. Dzau VJ; Mudgett-Hunter M; Haber E J Clin Endocrinol Metab; 1986 Feb; 62(2):424-8. PubMed ID: 3510227 [TBL] [Abstract][Full Text] [Related]
35. Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Cameron CE; Burstein H; Bizub-Bender D; Ridky T; Weber IT; Wlodawer A; Skalka AM; Leis J Adv Exp Med Biol; 1995; 362():399-406. PubMed ID: 8540349 [No Abstract] [Full Text] [Related]
39. [Secretases as therapeutic targets for the treatment of Alzheimer's disease]. Dejaegere T; de Strooper B Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081 [TBL] [Abstract][Full Text] [Related]
40. Comparisons of the three-dimensional structures, specificities and glycosylation of renins, yeast proteinase A and cathepsin D. Aguilar CF; Dhanaraj V; Guruprasad K; Dealwis C; Badasso M; Cooper JB; Wood SP; Blundell TL Adv Exp Med Biol; 1995; 362():155-66. PubMed ID: 8540315 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]